Building the biological data layer for AI

Alphabiome is the AI layer for drug development. We read the raw bacterial, viral, and host DNA that has no reference map, computing over signal others cannot, to reveal which therapies work, in which patients and why.

Discover Alphabiome

Learn more about how Alphabiome’s groundbreaking technology is opening new frontiers in precision medicine.

About Us

Reading the biology that decides who responds

The biology that determines treatment response is hidden in raw genetic signal. Alphabiome reads it reference-free, across human, bacterial, viral, and fungal DNA, finding the patterns that separate responders from non-responders and turning them into predictive intelligence for drug development.

What We Do

Tokenize raw genetic sequencing data directly, reference-free, across human, bacterial, viral, fungal and other DNA.
Learn latent biological structure across trillions of DNA fragments, beyond species, genes, pathways and reference genomes.
Convert raw DNA data into AI-usable tokens that can power prediction, stratification, mechanism discovery and therapeutic decision-making.

Science & News

16/04/2026

Expanding to Dermatology: Response Prediction Across 8 Therapies

Alphabiome extends its biological intelligence layer to dermatology, developing predictive biomarkers across three inflammatory skin conditions and eight therapies.

04/02/2026

IBD Study Complete: Predictive Biomarkers Identified for 7 Biologics

Alphabiome has completed its inflammatory bowel disease study, identifying predictive biomarkers for seven biologic therapies across two indications: Crohn’s disease and ulcerative colitis. From baseline gut metagenomic data alone, our reference-independent AI forecasts which patients will respond to each therapy, moving precision treatment upstream of the first dose.

21/11/2025

Peer-Reviewed in Frontiers: Our AI Predicts Response Across 10 Farms

A peer-reviewed Frontiers study validated Alphabiome’s reference-independent AI across 10 farms and 339 cows, predicting biological response directly from raw microbial DNA.

25/11/2025

Predicting Biologic Response in IBD

Alphabiome’s reference-independent AI now reaches human disease. In inflammatory bowel disease, our metagenomic engine reads baseline gut DNA, including bacterial, viral, and host, to predict which patients will respond to biologic therapy before treatment begins. The same predictive capability validated across commercial farms, applied where it matters most: the biological intelligence layer for drug development.

25/09/2025

Independent Validation: Our AI Predicts Response to a Second Additive

A controlled trial validated Alphabiome’s metagenomic AI on a monensin feed additive, a second and independent test of the same predictive engine. By reading microbial DNA directly, the model forecasts biological response across different interventions, not one compound. Evidence that the biological intelligence layer generalizes, the same capability we bring to drug development.

06/05/2025

Alphabiome Unveils Revolutionary AI Technology for Microbiome Decoding

Yahoo Finance- Using proprietary algorithms and advanced modeling, Alphabiome deciphers hidden microbial DNA to accurately predict individual drug response — setting a new standard in personalized medicine.

06/05/2025

AI That Predicts Drug Response Powered by the Microbiome

Health Technolog Net- Alphabiome’s proprietary platform analyzes microbial DNA beyond reference genomes, delivering unmatched accuracy in forecasting therapeutic outcomes.